Latest Asia Pacific News

Delegat Group delivered record operating earnings and cash flow in FY26, but reported profit fell after a NZ$8.7 million impairment and other fair-value adjustments. The NZX-listed wine company is forecasting higher case sales and operating NPAT of NZ$62 million to NZ$66 million for FY27.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.

International Graphite has arranged approximately $1.5 million in non-dilutive finance with National Australia Bank to fund construction of its Collie graphite processing facility. The project remains targeted for production building completion in Q2 2027, but the funding adds future repayment obligations as the company moves closer to commissioning.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

AdAlta says a 10-year, up to US$120 million agreement between manufacturing partner Oribiotech and an undisclosed commercial-stage biopharmaceutical company validates its choice of IRO automation for future cellular immunotherapies. The deal does not create direct revenue for AdAlta, and its lead asset EW-001 will continue with a separate manufacturing process.

Latrobe Magnesium has received a non-binding US$15 million Letter of Support from a confidential US financial institution for the feasibility study on its proposed 50 ktpa South Carolina magnesium plant. The funding remains conditional on matching finance, due diligence, approvals and definitive agreements.

Hydrix has secured a three-year contract with Singapore’s National Heart Centre to deploy the Implicity remote cardiac monitoring platform. The agreement is expected to generate about A$0.625 million, although the final value depends on patient volumes and implementation.

Tamboran Resources and its joint venture partner have begun gas commissioning at the Sturt Plateau Compression Facility, a critical step toward delivering natural gas to the Northern Territory market under a long-term contract.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

ClearVue Technologies saw a 35% revenue decline to $161,000 and a $11 million net loss in FY2026, driven by a major operational overhaul and significant product certification efforts. Despite the financial setback, the company expanded into new markets and secured key commercial projects.

X2M Connect Limited lifted revenue by 38% to $8.94 million in FY26, halving its net loss while laying groundwork for a new data centre business.